Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03639311 |
|---|---|
| Brief Title: | Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study |
| First Submitted : | August 10, 2018 |
| First Submitted that Met QC Criteria : | August 20, 2018 |
| First Posted : | August 21, 2018 |
| Results First Submitted : | November 20, 2020 |
| Results First Submitted that Met QC Criteria : | January 13, 2021 |
| Results First Posted : | January 15, 2021 |
| Last Update Submitted that Met QC Criteria : | February 23, 2021 |
| Last Update Posted : | March 22, 2021 |